HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 425 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $223,279 | +5.4% | 5,845 | -0.5% | 0.00% | 0.0% |
| Q2 2023 | $211,875 | +98907.0% | 5,874 | +5.0% | 0.00% | 0.0% |
| Q1 2023 | $214 | -44.1% | 5,593 | -16.8% | 0.00% | -33.3% |
| Q4 2022 | $383 | -99.9% | 6,723 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $300,000 | +0.3% | 6,723 | -1.0% | 0.00% | 0.0% |
| Q2 2022 | $299,000 | +10.3% | 6,791 | 0.0% | 0.00% | +50.0% |
| Q1 2022 | $271,000 | +35.5% | 6,791 | +17.7% | 0.00% | +100.0% |
| Q4 2021 | $200,000 | -18.0% | 5,771 | -4.0% | 0.00% | 0.0% |
| Q3 2021 | $244,000 | -51.3% | 6,010 | -45.5% | 0.00% | -66.7% |
| Q2 2021 | $501,000 | +8.9% | 11,037 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $460,000 | -2.3% | 11,037 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $471,000 | +141.5% | 11,037 | +48.9% | 0.00% | +50.0% |
| Q3 2020 | $195,000 | -53.2% | 7,413 | -52.4% | 0.00% | -50.0% |
| Q2 2020 | $417,000 | +89.5% | 15,567 | +27.4% | 0.00% | +100.0% |
| Q1 2020 | $220,000 | -31.7% | 12,220 | -32.7% | 0.00% | -33.3% |
| Q4 2019 | $322,000 | +22.0% | 18,150 | +6.6% | 0.00% | +50.0% |
| Q3 2019 | $264,000 | +172.2% | 17,030 | +202.5% | 0.00% | +100.0% |
| Q2 2019 | $97,000 | +6.6% | 5,630 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $91,000 | +11.0% | 5,630 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $82,000 | -19.6% | 5,630 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $102,000 | +5.2% | 5,630 | -2.4% | 0.00% | 0.0% |
| Q2 2018 | $97,000 | -14.2% | 5,770 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $113,000 | -8.9% | 5,770 | -5.7% | 0.00% | 0.0% |
| Q4 2017 | $124,000 | +17.0% | 6,120 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $106,000 | +35.9% | 6,120 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $78,000 | -1.3% | 6,120 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $79,000 | +12.9% | 6,120 | -13.8% | 0.00% | 0.0% |
| Q4 2016 | $70,000 | +180.0% | 7,100 | +238.1% | 0.00% | – |
| Q3 2016 | $25,000 | +212.5% | 2,100 | +133.3% | 0.00% | – |
| Q2 2016 | $8,000 | -11.1% | 900 | 0.0% | 0.00% | – |
| Q1 2016 | $9,000 | – | 900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |